Aura Biosciences (NASDAQ:AURA) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Aura Biosciences (NASDAQ:AURA) in a research report report published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $21.00 price objective on the stock.

Aura Biosciences Stock Up 0.9 %

AURA stock opened at $10.36 on Thursday. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.44. The company has a market cap of $513.23 million, a PE ratio of -5.57 and a beta of 0.38. The business’s 50-day simple moving average is $7.69 and its 200 day simple moving average is $7.83.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. On average, equities research analysts anticipate that Aura Biosciences will post -1.8 EPS for the current year.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP grew its position in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after buying an additional 6,809 shares in the last quarter. American International Group Inc. boosted its holdings in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences during the first quarter valued at approximately $144,000. SG Americas Securities LLC boosted its holdings in Aura Biosciences by 52.0% during the fourth quarter. SG Americas Securities LLC now owns 19,140 shares of the company’s stock valued at $170,000 after purchasing an additional 6,546 shares in the last quarter. Finally, TBH Global Asset Management LLC boosted its holdings in Aura Biosciences by 82.3% during the fourth quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock valued at $534,000 after purchasing an additional 27,225 shares in the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.